Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock Has Consensus Target Price of $6.75

Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) have been assigned a consensus recommendation of “Hold” from the five brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $6.75.

Several equities research analysts have issued reports on HBIO shares. Stonex Financial lowered Harvard Bioscience from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. StoneX downgraded Harvard Bioscience from a “speculative buy” rating to a “hold” rating in a report on Wednesday. Weiss Ratings raised Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Benchmark increased their target price on Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a report on Wednesday, August 12th. Finally, Zacks Research initiated coverage on Harvard Bioscience in a research report on Tuesday, November 3rd. They set a “hold” rating on the stock.

Hedge Funds Weigh In On Harvard Bioscience

An institutional investor recently bought a new position in Harvard Bioscience stock. Meros Investment Management LP bought a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned 4.02% of Harvard Bioscience as of its most recent SEC filing. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Trading Down 4.8%

NASDAQ:HBIO opened at $9.22 on Friday. Harvard Bioscience has a 1 year low of $4.00 and a 1 year high of $10.20. The stock’s fifty day moving average price is $8.31 and its two-hundred day moving average price is $6.57. The company has a debt-to-equity ratio of 7.28, a current ratio of 1.76 and a quick ratio of 0.98. The company has a market cap of $42.14 million, a P/E ratio of -3.56 and a beta of 1.47.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Tuesday, November 10th. The medical instruments supplier reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.27. The company had revenue of $22.20 million during the quarter, compared to analyst estimates of $21.80 million. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 43.94%. As a group, analysts expect that Harvard Bioscience will post -2.44 EPS for the current year.

About Harvard Bioscience

Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.